{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:50:32Z","timestamp":1793163032717,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejpb.2025.114692","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:15:03Z","timestamp":1741695303000},"page":"114692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Intradermal delivery of teriflunomide loaded emulsomes using hollow microneedles for effective minimally invasive psoriasis management"],"prefix":"10.1016","volume":"210","author":[{"given":"Mariam","family":"Zewail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidy","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine El","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Abd-El-Azim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejpb.2025.114692_b0005","first-page":"CC14","article-title":"The serum levels of malondialdehyde, vitamin e and erythrocyte catalase activity in psoriasis patients","volume":"8","author":"Pujari","year":"2014","journal-title":"J. Clin. Diagn. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114692_b0010","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/antiox11020282","article-title":"The involvement of oxidative stress in psoriasis: a systematic review","volume":"11","author":"Dobric\u0103","year":"2022","journal-title":"Antioxidants"},{"issue":"9","key":"10.1016\/j.ejpb.2025.114692_b0015","first-page":"626","article-title":"Psoriasis","volume":"87","author":"Weigle","year":"2013","journal-title":"Am. Fam. Physician"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114692_b0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja","year":"2021","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114692_b0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/jfmpc.jfmpc_689_19","article-title":"Update on psoriasis: a review","volume":"9","author":"Rajguru","year":"2020","journal-title":"J. Family Med. Primary Care"},{"issue":"46","key":"10.1016\/j.ejpb.2025.114692_b0030","doi-asserted-by":"crossref","first-page":"29080","DOI":"10.1039\/D1RA06087B","article-title":"Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects","volume":"11","author":"Nordin","year":"2021","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114692_b0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/13510002.2018.1462027","article-title":"Proanthocyanidins: novel treatment for psoriasis that reduces oxidative stress and modulates Th17 and Treg cells","volume":"23","author":"Lai","year":"2018","journal-title":"Redox Rep."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114692_b0040","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1080\/10717544.2022.2110996","article-title":"Surface-tailoring of emulsomes for boosting brain delivery of vinpocetine via intranasal route: in vitro optimization and in vivo pharmacokinetic assessment","volume":"29","author":"Aldawsari","year":"2022","journal-title":"Drug Deliv."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114692_b0045","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3390\/ijms23052401","article-title":"Recent advances of microneedles and their application in disease treatment","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejpb.2025.114692_b0050","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3390\/pharmaceutics14081736","article-title":"Promising strategies for transdermal delivery of arthritis drugs: microneedle systems","volume":"14","author":"Wang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2025.114692_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mser.2016.03.001","article-title":"Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development","volume":"104","author":"Larraneta","year":"2016","journal-title":"Mater. Sci. Eng. R. Rep."},{"issue":"5","key":"10.1016\/j.ejpb.2025.114692_b0060","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.apsb.2021.03.013","article-title":"Nanomedicines for the treatment of rheumatoid arthritis: state of art and potential therapeutic strategies","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2025.114692_b0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejpb.2021.04.016","article-title":"Improved imiquimod-induced psoriasis like dermatitis using microneedles in mice","volume":"164","author":"Liang","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114692_b0070","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jconrel.2022.06.027","article-title":"Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer","author":"Abd-El-Azim","year":"2022","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114692_b0075","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.apsb.2019.03.007","article-title":"Recent advances of microneedles for biomedical applications: drug delivery and beyond","volume":"9","author":"Yang","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2025.114692_b0080","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10530","article-title":"Customized flexible hollow microneedles for psoriasis treatment with reduced\u2010dose drug","author":"Ren","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ejpb.2025.114692_b0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/OARRR.S9448","article-title":"Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis","author":"Jones","year":"2010","journal-title":"Open Access Rheumatol."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114692_b0090","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double\u2010blind, randomized, placebo\u2010controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis & Rheumatism: Off. J. Am. College Rheumatol."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114692_b0095","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.ejpb.2025.114692_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121939","article-title":"Hyaluronic acid coated teriflunomide (A771726) loaded lipid carriers for the oral management of rheumatoid arthritis","volume":"623","author":"Zewail","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.ejpb.2025.114692_b0105","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/archderm.140.10.1288","article-title":"Leflunomide in psoriasis and psoriatic arthritis: a preliminary study","volume":"140","author":"Thami","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejpb.2025.114692_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2017.08.010","article-title":"Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases","author":"Prosperi","year":"2017","journal-title":"Seminars in Immunology, Elsevier"},{"issue":"7","key":"10.1016\/j.ejpb.2025.114692_b0115","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.xphs.2021.04.001","article-title":"Intra-articular dual drug delivery for synergistic rheumatoid arthritis treatment","volume":"110","author":"Zewail","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114692_b0120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00002512-200926050-00003","article-title":"Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment","volume":"26","author":"Alivernini","year":"2009","journal-title":"Drugs Aging"},{"issue":"10","key":"10.1016\/j.ejpb.2025.114692_b0125","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3390\/pharmaceutics14102005","article-title":"Development and evaluation of novel leflunomide SPION bioemulsomes for the intra-articular treatment of arthritis","volume":"14","author":"Abbas","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2025.114692_b0130","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijpharm.2009.10.006","article-title":"Surface charged temoporfin-loaded flexible vesicles: in vitro skin penetration studies and stability","volume":"384","author":"Dragicevic-Curic","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114692_b0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.xphs.2021.08.023","article-title":"Resveratrol-loaded vesicular elastic nanocarriers gel in imiquimod-induced psoriasis treatment: in vitro and in vivo evaluation","volume":"111","author":"Elgewelly","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114692_b0140","first-page":"1","article-title":"Combined photodynamic therapy and hollow microneedle approach for effective non-invasive delivery of hypericin for the management of imiquimod-induced psoriasis","author":"Zewail","year":"2024","journal-title":"J. Drug Target. (Just-Accepted)"},{"issue":"22","key":"10.1016\/j.ejpb.2025.114692_b0145","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2217\/nnm-2021-0137","article-title":"Novel bioemulsomes for baicalin oral lymphatic targeting: development, optimization and pharmacokinetics","volume":"16","author":"Rizk","year":"2021","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.ejpb.2025.114692_b0150","article-title":"Emerging role of vesicular carriers for therapy of visceral leishmaniasis: conventional versus novel","volume":"27","author":"Kumar","year":"2010","journal-title":"Critical Reviews\u2122 in Therapeutic Drug Carrier Systems"},{"issue":"12","key":"10.1016\/j.ejpb.2025.114692_b0155","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s12272-015-0630-7","article-title":"Preparation and performance evaluation of emulsomes as a drug delivery system for silybin","volume":"38","author":"Zhou","year":"2015","journal-title":"Arch. Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114692_b0160","first-page":"133","article-title":"Emulsomes: an emerging vesicular drug delivery system","volume":"3","author":"Kumar","year":"2013","journal-title":"J. Drug Deliv. Therapeutics"},{"issue":"4","key":"10.1016\/j.ejpb.2025.114692_b0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2174\/138920101604150218112656","article-title":"Emulsomes meet S-layer proteins: an emerging targeted drug delivery system","volume":"16","author":"Ucisik","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114692_b0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nano.2008.08.003","article-title":"Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery","volume":"5","author":"Paliwal","year":"2009","journal-title":"Nanomed.: Nanotech. Bio. Med."},{"key":"10.1016\/j.ejpb.2025.114692_b0175","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.2147\/IJN.S263797","article-title":"Anticancer activity of thymoquinone cubic phase nanoparticles against human breast cancer: formulation, cytotoxicity and subcellular localization","volume":"15","author":"Mehanna","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114692_b0180","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1080\/10717544.2022.2079770","article-title":"Lipidic cubic-phase leflunomide nanoparticles (cubosomes) as a potential tool for breast cancer management","volume":"29","author":"Zewail","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2025.114692_b0185","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2147\/IJN.S45313","article-title":"Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect","volume":"8","author":"Rahman","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejpb.2025.114692_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118447","article-title":"Coated nanostructured lipid carriers targeting the joints\u2013an effective and safe approach for the oral management of rheumatoid arthritis","volume":"567","author":"Zewail","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114692_b0195","doi-asserted-by":"crossref","first-page":"9783","DOI":"10.2147\/IJN.S278688","article-title":"Bilosomes as promising nanovesicular carriers for improved transdermal delivery: construction, in vitro optimization, ex vivo permeation and in vivo evaluation","volume":"15","author":"Ahmed","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114692_b0200","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/10717544.2022.2044938","article-title":"Development and optimization of curcumin analog nano-bilosomes using 21.31 full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma: in-vitro evaluation, in-vivo safety assay","volume":"29","author":"Abbas","year":"2022","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114692_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08982104.2019.1577256","article-title":"Bilosomes as a novel carrier for the cutaneous delivery for dapsone as a potential treatment of acne: preparation, characterization and in vivo skin deposition assay","volume":"30","author":"El-Nabarawi","year":"2020","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejpb.2025.114692_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121244","article-title":"Superparamagnetic iron oxide loaded chitosan coated bilosomes for magnetic nose to brain targeting of resveratrol","volume":"610","author":"Abbas","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2025.114692_b0215","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.xphs.2018.04.007","article-title":"Superparamagnetic iron oxide\u2013loaded lipid nanocarriers incorporated in thermosensitive in situ gel for magnetic brain targeting of clonazepam","volume":"107","author":"Abbas","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114692_b0220","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/10837450.2021.1920617","article-title":"PLA-coated Imwitor\u00ae 900 K-based herbal colloidal carriers as novel candidates for the intra-articular treatment of arthritis","volume":"26","author":"Abbas","year":"2021","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2025.114692_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2022.103527","article-title":"Development and optimization of solid lipid nanoparticles coated with chitosan and poly (2-ethyl-2-oxazoline) for ocular drug delivery of ciprofloxacin","volume":"74","author":"Onugwu","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114692_b0230","unstructured":"V.V. Yuzhakov, Microneedle array, patch, and applicator for transdermal drug delivery, https:\/\/patents.google.com\/patent\/WO2007081430A3\/en, 2010."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114692_b0235","first-page":"32","article-title":"The AdminPen\u2122 microneedle device for painless & convenient drug delivery","volume":"10","author":"Yuzhakov","year":"2010","journal-title":"Drug Deliv. Tech."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2025.114692_b0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2014.05.042","article-title":"A proposed model membrane and test method for microneedle insertion studies","volume":"472","author":"Larra\u00f1eta","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114692_b0245","first-page":"163","article-title":"Skin models for the testing of transdermal drugs","volume":"8","author":"Abd","year":"2016","journal-title":"Clin. Pharmacol.: Adv. Appl."},{"issue":"9","key":"10.1016\/j.ejpb.2025.114692_b0250","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/pharmaceutics12090789","article-title":"Advanced characterization of imiquimod-induced psoriasis-like mouse model","volume":"12","author":"Jabeen","year":"2020","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ejpb.2025.114692_b0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137890","article-title":"Using imiquimod-induced psoriasis-like skin as a model to measure the skin penetration of anti-psoriatic drugs","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejpb.2025.114692_b0260","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/1346-8138.13695","article-title":"Involvement of high mobility group box-1 in imiquimod-induced psoriasis-like mice model","volume":"44","author":"Chen","year":"2017","journal-title":"J. Dermatol."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114692_b0265","doi-asserted-by":"crossref","DOI":"10.1080\/00015550510011600","article-title":"Effect of psoriasis activity on metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in plasma and lesional scales","volume":"86","author":"Flisiak","year":"2006","journal-title":"Acta Derm. Venereol."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114692_b0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","article-title":"NF-\u03baB: an essential transcription factor in psoriasis","volume":"69","author":"Goldminz","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.ejpb.2025.114692_b0275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1134\/S102279541109016X","article-title":"Genes expression of metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12) associated with psoriasis","volume":"47","author":"Starodubtseva","year":"2011","journal-title":"Russ. J. Genet."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114692_b0280","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2025.114692_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.760852","article-title":"The role of glutathione-S transferase in psoriasis and associated comorbidities and the effect of dimethyl fumarate in this pathway","volume":"9","author":"Campione","year":"2022","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114692_b0290","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/rheumatology\/keh032","article-title":"Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings","volume":"43","author":"Myers","year":"2004","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.ejpb.2025.114692_b0295","article-title":"Activity of superoxide dismutase and catalase and the level of lipid peroxidation products reactive with TBA in patients with psoriasis","volume":"8","author":"Drewa","year":"2002","journal-title":"Med. Sci. Monitor: Int. Med. J. Exp. Clin. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114692_b0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/09546634.2011.595383","article-title":"Leflunomide: dermatologic perspective","volume":"24","author":"Sehgal","year":"2013","journal-title":"J. Dermatol. Treat."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:50:40Z","timestamp":1753743040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":60,"alternative-id":["S0939641125000682"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114692","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intradermal delivery of teriflunomide loaded emulsomes using hollow microneedles for effective minimally invasive psoriasis management","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114692"}}